GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Gross Margin %

ANVS (Annovis Bio) Gross Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Annovis Bio's Gross Profit for the three months ended in Dec. 2024 was $0.00 Mil. Annovis Bio's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Annovis Bio's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Annovis Bio's Gross Margin % or its related term are showing as below:


ANVS's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.89
* Ranked among companies with meaningful Gross Margin % only.

Annovis Bio had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Annovis Bio was 0.00% per year.


Annovis Bio Gross Margin % Historical Data

The historical data trend for Annovis Bio's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Gross Margin % Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Margin %
Get a 7-Day Free Trial - - - - -

Annovis Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Annovis Bio's Gross Margin %

For the Biotechnology subindustry, Annovis Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Annovis Bio's Gross Margin % falls into.


;
;

Annovis Bio Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Annovis Bio's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as

Gross Margin % (A: Dec. 2024 )=Gross Profit (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Annovis Bio's Gross Margin for the quarter that ended in Dec. 2024 is calculated as


Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Annovis Bio  (NYSE:ANVS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Annovis Bio had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Annovis Bio Gross Margin % Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio Business Description

Traded in Other Exchanges
Address
101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831